Christina Poh, MD, discusses results from the phase 3 inMIND study of tafasitamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.
Christina Poh, MD
Advertisement
Articles by Christina Poh, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5